Sorrento Therapeutics Stock Price, News & Analysis (NASDAQ:SRNE)

$9.10 +0.70 (+8.33 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$9.10
Today's Range$8.50 - $9.10
52-Week Range$1.50 - $9.55
Volume2.31 million shs
Average Volume2.94 million shs
Market Capitalization$781.98 million
P/E Ratio-21.67
Dividend YieldN/A
Beta1.94

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SRNE
CUSIPN/A
Phone+1-858-2034100

Debt

Debt-to-Equity Ratio0.18%
Current Ratio0.54%
Quick Ratio0.54%

Price-To-Earnings

Trailing P/E Ratio-21.6666666666667
Forward P/E Ratio-23.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.15 million
Price / Sales92.33
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book5.35

Profitability

Trailing EPS($0.42)
Net Income$-60,920,000.00
Net Margins-15.62%
Return on Equity-26.98%
Return on Assets-6.39%

Miscellaneous

Employees154
Outstanding Shares82,690,000

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) issued its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. The biopharmaceutical company earned $1.10 million during the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a negative return on equity of 26.98% and a negative net margin of 15.62%. View Sorrento Therapeutics' Earnings History.

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2018?

5 analysts have issued 1-year target prices for Sorrento Therapeutics' stock. Their forecasts range from $7.00 to $35.00. On average, they expect Sorrento Therapeutics' stock price to reach $16.00 in the next twelve months. View Analyst Ratings for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:

  • William S. Marth, Independent Chairman of the Board (Age 61)
  • Henry H. Ji Ph.D., President, Chief Executive Officer, Director (Age 63)
  • Kevin Herde, Chief Financial Officer, Executive Vice President
  • Mike Royal M.D., Executive Vice President - Clinical and Regulatory Affairs (Age 61)
  • Miranda Jayne Toledano, Executive Vice President - Corporate Development
  • George Uy, Executive Vice President, Chief Commercial Officer (Age 59)
  • David Miao, Chief Technology Officer (Age 51)
  • Jaisim Shah, Director (Age 54)
  • Yue Wu Ph.D., Director
  • David H. Deming, Independent Director (Age 62)

Who owns Sorrento Therapeutics stock?

Sorrento Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.52%), BlackRock Inc. (1.17%), Deutsche Bank AG (0.12%), Bank of New York Mellon Corp (0.07%), Acadian Asset Management LLC (0.06%) and Gotham Asset Management LLC (0.05%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Who sold Sorrento Therapeutics stock? Who is selling Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG. Company insiders that have sold Sorrento Therapeutics company stock in the last year include Abg Management Ltd and Pacific Medtech (Bvi) Ltd Asia. View Insider Buying and Selling for Sorrento Therapeutics.

Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Acadian Asset Management LLC, Gotham Asset Management LLC, Alambic Investment Management L.P., Monashee Investment Management LLC, MYDA Advisors LLC and Bank of New York Mellon Corp. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $9.10.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $781.98 million and generates $8.15 million in revenue each year. The biopharmaceutical company earns $-60,920,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Sorrento Therapeutics employs 154 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 Directors Pl, SAN DIEGO, CA 92121-3836, United States. The biopharmaceutical company can be reached via phone at +1-858-2034100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (SRNE)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sorrento Therapeutics (NASDAQ:SRNE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$15.00$12.40$12.60
Price Target Upside: 82.86% upside93.55% upside439.13% upside663.64% upside

Sorrento Therapeutics (NASDAQ:SRNE) Consensus Price Target History

Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018HC WainwrightReiterated RatingBuy$35.00MediumView Rating Details
1/19/2018OppenheimerReiterated RatingBuy$9.00HighView Rating Details
8/3/2017Roth CapitalInitiated CoverageBuy$7.00HighView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy -> Buy$30.00 -> $20.00HighView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Sorrento Therapeutics (NASDAQ:SRNE) Earnings History and Estimates Chart

Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ SRNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.20)$4.67 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.33)($0.45)$4.02 million$4.87 millionViewN/AView Earnings Details
3/21/2017Q4 2016($0.27)($0.44)$2.99 million$4.02 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.19)$2.24 millionViewN/AView Earnings Details
8/8/2016Q2 2016($0.17)($0.28)$1.11 million$0.90 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.37)($0.63)$1.34 million$0.99 millionViewN/AView Earnings Details
3/15/2016Q4 2015($0.63)$1.34 millionViewN/AView Earnings Details
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
8/7/2015Q2 2015($0.32)($0.30)$0.95 million$1.17 millionViewN/AView Earnings Details
5/5/2015Q1 2015($0.14)($0.29)$5.85 million$0.98 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.28)$0.80 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
4/1/2014Q4 2013($0.28)($0.35)$0.10 millionViewN/AView Earnings Details
11/14/2013Q3 2013($0.28)($0.23)$0.08 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.26)$0.14 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.01)$0.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sorrento Therapeutics (NASDAQ:SRNE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.29)($0.29)($0.29)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.26)($0.26)($0.26)
Q4 20181($0.24)($0.24)($0.24)
Q1 20191($0.22)($0.22)($0.22)
Q2 20191($0.19)($0.19)($0.19)
Q3 20191($0.20)($0.20)($0.20)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sorrento Therapeutics (NASDAQ SRNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 12.32%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ SRNE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2018Abg Management LtdMajor ShareholderSell150,000$7.19$1,078,500.00View SEC Filing  
2/5/2018Abg Management LtdMajor ShareholderSell70,721$8.00$565,768.00View SEC Filing  
1/30/2018Abg Management LtdMajor ShareholderSell310,000$7.64$2,368,400.00View SEC Filing  
1/24/2018Pacific Medtech (Bvi) Ltd AsiaMajor ShareholderSell684,288$7.56$5,173,217.28View SEC Filing  
6/15/2017Henry JiInsiderBuy29,001$1.81$52,491.81139,776View SEC Filing  
6/15/2017Jaisim ShahDirectorBuy10,002$1.79$17,903.58112,633View SEC Filing  
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00139,776View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.0039,776View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.0037,776View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.0010,000View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.007,000View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.005,000View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00720,174View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85720,174View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32720,174View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96736,146View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80736,146View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00859,238View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00500View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.9217,776View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.0414,888View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sorrento Therapeutics (NASDAQ SRNE) News Headlines

Source:
DateHeadline
Sorrento Therapeutics (SRNE) "Buy" Rating Reiterated at HC WainwrightSorrento Therapeutics' (SRNE) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - February 20 at 11:30 AM
Sorrento Therapeutics (SRNE): Celularity Bridges Path To IPO - HCWainwright - StreetInsider.comSorrento Therapeutics (SRNE): Celularity Bridges Path To IPO - HCWainwright - StreetInsider.com
www.streetinsider.com - February 20 at 8:17 AM
Sorrento Therapeutics Inc (SRNE) Given Consensus Recommendation of "Buy" by AnalystsSorrento Therapeutics Inc (SRNE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 19 at 1:46 AM
Sorrento Therapeutics (SRNE) Rating Increased to Strong-Buy at BidaskClubSorrento Therapeutics (SRNE) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - February 17 at 6:56 AM
3 Things In Biotech You Should Learn Today: February 16, 20183 Things In Biotech You Should Learn Today: February 16, 2018
seekingalpha.com - February 16 at 8:19 AM
Why Sorrento Therapeutics Jumped Higher TodayWhy Sorrento Therapeutics Jumped Higher Today
finance.yahoo.com - February 15 at 5:20 PM
Does Sorrento Therapeutics Inc’s (NASDAQ:SRNE) Past Performance Indicate A Stronger Future?Does Sorrento Therapeutics Inc’s (NASDAQ:SRNE) Past Performance Indicate A Stronger Future?
finance.yahoo.com - February 15 at 9:19 AM
$12.80 Million in Sales Expected for Sorrento Therapeutics Inc (SRNE) This Quarter$12.80 Million in Sales Expected for Sorrento Therapeutics Inc (SRNE) This Quarter
www.americanbankingnews.com - February 13 at 11:14 AM
Sorrento Therapeutics Inc (SRNE) Expected to Post Earnings of -$0.26 Per ShareSorrento Therapeutics Inc (SRNE) Expected to Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - February 11 at 5:14 AM
Sorrento Therapeutics Inc (SRNE) Major Shareholder Abg Management Ltd Sells 150,000 SharesSorrento Therapeutics Inc (SRNE) Major Shareholder Abg Management Ltd Sells 150,000 Shares
www.americanbankingnews.com - February 8 at 9:20 AM
Today’s Research Reports on Trending Tickers: Argos Therapeutics and Sorrento TherapeuticsToday’s Research Reports on Trending Tickers: Argos Therapeutics and Sorrento Therapeutics
finance.yahoo.com - February 7 at 9:41 AM
Abg Management Ltd Sells 70,721 Shares of Sorrento Therapeutics Inc (SRNE) StockAbg Management Ltd Sells 70,721 Shares of Sorrento Therapeutics Inc (SRNE) Stock
www.americanbankingnews.com - February 7 at 9:20 AM
Sorrentos and Yuhans Joint Venture, ImmuneOncia, receives ... - GlobeNewswire (press release)Sorrento's and Yuhan's Joint Venture, ImmuneOncia, receives ... - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:41 PM
Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South KoreaSorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea
finance.yahoo.com - February 5 at 9:40 AM
Sorrento Therapeutics, Inc. Chairman/CEO letter to stockholdersSorrento Therapeutics, Inc. Chairman/CEO letter to stockholders
finance.yahoo.com - February 5 at 9:40 AM
Head-To-Head Comparison: Sorrento Therapeutics (SRNE) and Deciphera Pharmaceuticals (DCPH)Head-To-Head Comparison: Sorrento Therapeutics (SRNE) and Deciphera Pharmaceuticals (DCPH)
www.americanbankingnews.com - February 3 at 5:16 AM
Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18 - GlobeNewswire (press release)Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18 - GlobeNewswire (press release)
globenewswire.com - February 2 at 3:49 PM
Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18
finance.yahoo.com - February 2 at 9:31 AM
Sorrento Therapeutics (SRNE) Receives "Buy" Rating from HC WainwrightSorrento Therapeutics (SRNE) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - February 1 at 1:52 PM
Abg Management Ltd Sells 310,000 Shares of Sorrento Therapeutics Inc (SRNE) StockAbg Management Ltd Sells 310,000 Shares of Sorrento Therapeutics Inc (SRNE) Stock
www.americanbankingnews.com - January 31 at 12:16 PM
BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001
finance.yahoo.com - January 29 at 9:48 AM
China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal AntibodyChina Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody
finance.yahoo.com - January 29 at 9:48 AM
Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.80 MillionSorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.80 Million
www.americanbankingnews.com - January 27 at 6:44 AM
Building in Biotech, Adding to TwitterBuilding in Biotech, Adding to Twitter
finance.yahoo.com - January 26 at 3:44 PM
Sorrento Therapeutics Inc (SRNE) Major Shareholder Sells $5,173,217.28 in StockSorrento Therapeutics Inc (SRNE) Major Shareholder Sells $5,173,217.28 in Stock
www.americanbankingnews.com - January 25 at 9:12 PM
Sorrento Therapeutics Inc (SRNE) Given Consensus Rating of "Buy" by AnalystsSorrento Therapeutics Inc (SRNE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 25 at 1:30 AM
Why Sorrento Therapeutics Inc Jumped Higher Today - Motley FoolWhy Sorrento Therapeutics Inc Jumped Higher Today - Motley Fool
www.fool.com - January 24 at 8:07 AM
Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast FacilitySorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility
finance.yahoo.com - January 24 at 8:07 AM
Sorrento Therapeutics (SRNE) Buy Rating Reiterated at HC WainwrightSorrento Therapeutics' (SRNE) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 23 at 7:32 AM
Why Sorrento Therapeutics Inc Jumped Higher TodayWhy Sorrento Therapeutics Inc Jumped Higher Today
www.fool.com - January 22 at 12:33 PM
Sorrento Therapeutics to Present at Noble Capital Markets Fourteenth Annual Investor Conference on 01/29/18 - GlobeNewswire (press release)Sorrento Therapeutics to Present at Noble Capital Markets' Fourteenth Annual Investor Conference on 01/29/18 - GlobeNewswire (press release)
www.globenewswire.com - January 22 at 8:05 AM
Sorrento Therapeutics to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference on 01/29/18Sorrento Therapeutics to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference on 01/29/18
finance.yahoo.com - January 22 at 8:05 AM
Oppenheimer Reaffirms "Buy" Rating for Sorrento Therapeutics (SRNE)Oppenheimer Reaffirms "Buy" Rating for Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - January 19 at 8:04 PM
Critical Analysis: Sorrento Therapeutics (SRNE) & Achaogen (AKAO)Critical Analysis: Sorrento Therapeutics (SRNE) & Achaogen (AKAO)
www.americanbankingnews.com - January 18 at 9:36 PM
Sorrento Therapeutics (SRNE) Rating Reiterated by HC WainwrightSorrento Therapeutics (SRNE) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - January 16 at 8:08 AM
Sorrento Therapeutics Inc (SRNE) Short Interest UpdateSorrento Therapeutics Inc (SRNE) Short Interest Update
www.americanbankingnews.com - January 14 at 2:32 AM
Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.03 MillionSorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.03 Million
www.americanbankingnews.com - January 10 at 8:46 PM
Sorrento Therapeutics (SRNE) Lifted to "Buy" at BidaskClubSorrento Therapeutics (SRNE) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - January 6 at 3:36 PM
Sorrento Therapeutics (SRNE) Says it Will Present Potential Game ... - StreetInsider.comSorrento Therapeutics (SRNE) Says it Will Present Potential 'Game ... - StreetInsider.com
www.streetinsider.com - January 2 at 3:46 PM
Sorrento Therapeutics to Present Potential “Game-Changer” Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T TherapiesSorrento Therapeutics to Present Potential “Game-Changer” Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T Therapies
finance.yahoo.com - January 2 at 11:12 AM
Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 11:09 AM
Sorrento Therapeutics Inc (SRNE) Receives Consensus Recommendation of "Buy" from BrokeragesSorrento Therapeutics Inc (SRNE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 31 at 1:58 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : December 27, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:26 PM
Sorrento Therapeutics (SRNE) Upgraded at BidaskClubSorrento Therapeutics (SRNE) Upgraded at BidaskClub
www.americanbankingnews.com - December 24 at 12:26 AM
SRNE Dec 2017 7.500 callSRNE Dec 2017 7.500 call
finance.yahoo.com - December 6 at 11:47 AM
$4.23 Million in Sales Expected for Sorrento Therapeutics Inc (SRNE) This Quarter$4.23 Million in Sales Expected for Sorrento Therapeutics Inc (SRNE) This Quarter
www.americanbankingnews.com - December 6 at 2:46 AM
Sorrento Therapeutics Inc (SRNE) Given Average Rating of "Buy" by BrokeragesSorrento Therapeutics Inc (SRNE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 6 at 1:46 AM
-$0.23 EPS Expected for Sorrento Therapeutics, Inc. (SRNE) This Quarter-$0.23 EPS Expected for Sorrento Therapeutics, Inc. (SRNE) This Quarter
www.americanbankingnews.com - December 4 at 11:26 PM
Sorrento Therapeutics, Inc. (SRNE) Given a $6.00 Price Target by Oppenheimer Holdings, Inc. AnalystsSorrento Therapeutics, Inc. (SRNE) Given a $6.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017
finance.yahoo.com - November 18 at 11:56 AM

SEC Filings

Sorrento Therapeutics (NASDAQ:SRNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sorrento Therapeutics (NASDAQ:SRNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sorrento Therapeutics (NASDAQ SRNE) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.